Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18544098 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL694280 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL2024759 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL694279 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL375241 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL5579709 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL694281 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL201852 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL4002727 | 0.92 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1312359 | 0.92 | HSD17B10 (0.53) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 939 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011119-A | Preparation method and application of bionic collagen cyclohexapeptide | 成都欣肽生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2025124444-A1 | USE OF HYDROXYPROLINE AND DERIVATIVE THEREOF, BIOLOGICAL HERBICIDE, BROAD-SPECTRUM HERBICIDE, AND WEED CONTROL METHOD | 三亚市国家耐盐碱水稻技术创新中心 | 2025-06-19 | — | — | WO | claimed |
| CN-120130489-A | Application of hydroxyproline and derivatives thereof, biological herbicide, broad-spectrum herbicide and weed control method | 三亚市国家耐盐碱水稻技术创新中心 | 2025-06-13 | — | — | CN | claimed |
| CN-119019539-A | Iterative index synthesis method of long-chain collagen-like polypeptide | 上海欣肽生物科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-118684615-A | Synthesis method of difluoro cyclobutane proline and derivative thereof | 吉尔多肽生物制药(大连市)有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-114573562-B | Niacin-containing triazole compound and preparation method and application thereof | 西安交通大学 | 2023-07-07 | — | — | CN | claimed |
| CN-114573567-B | Indazole cyclotriazole compound and preparation method and application thereof | 西安交通大学 | 2023-05-02 | — | — | CN | claimed |
| CN-114437113-B | Thiazolopyridine cyclotriazole compound, and preparation method and application thereof | 西安交通大学 | 2023-05-02 | — | — | CN | claimed |
| CN-114437037-B | Compound containing pyridine-bis-triazole as well as preparation method and application thereof | 西安交通大学 | 2023-04-07 | — | — | CN | claimed |
| CN-110724138-B | Synthesis method of (2S) -4-oxo-2- (3-thiazolidinyl carbonyl) -1-pyrrolidine carboxylic acid tert-butyl ester | 山东邹平大展新材料有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-111378007-A | Method for preparing palippivir by using second-generation Hoveyda-Grubbs catalyst | 杭州勇诚睿生物科技有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-109796439-B | Hydroxyproline peptide derivative and preparation method and application thereof | 西安交通大学 | 2020-05-19 | — | — | CN | claimed |
| CN-109761957-B | Hydroxyproline-containing compound and preparation method and application thereof | 西安交通大学 | 2020-05-19 | — | — | CN | claimed |
| CN-110724138-A | Synthesis method of (2S) -4-oxo-2- (3-thiazolidinyl carbonyl) -1-pyrrolidine carboxylic acid tert-butyl ester | 山东邹平大展新材料有限公司 | 2020-01-24 | — | — | CN | claimed |
| CN-106256819-A | A kind of synthetic method of (4S) N Boc 4 methoxy L proline amine salt | 重庆博腾制药科技股份有限公司 | 2016-12-28 | — | — | CN | claimed |
| CN-105801462-A | Synthesis method of (4S) -N-Boc-4-methoxymethyl-L-proline | 重庆博腾制药科技股份有限公司 | 2016-07-27 | — | — | CN | claimed |
| CN-101695670-A | Catalysts for Baylis-Hillman reaction and preparation method thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2010-04-21 | — | — | CN | claimed |
| EP-2160392-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2010-03-10 | — | — | EP | claimed |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | claimed |
| WO-2008137779-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | HSD17B10 1531/4885CHRM2 4773/4885CHRM1 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.